Related Experiment Video
Updated: Apr 7, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
[Update on therapy of chronic heart failure. Innovations and studies from last year]
Sebastian Ewen1, Y Linicus2, M Böhm2
1Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str., Geb. 40, 66421, Homburg/Saar, Deutschland. Sebastian.Ewen@uks.eu.
Insights
This review highlights 2014 innovations in chronic heart failure (CHF) therapy, focusing on updated guidelines for established medications and new treatments like neprilysin inhibition. It also covers managing comorbidities such as atrial fibrillation and hyperkalemia.
Area of Science:
- Cardiology
- Internal Medicine
Context:
- Chronic heart failure (CHF) presents a significant global health challenge with rising prevalence.
- High morbidity and mortality necessitate standardized, evidence-based therapeutic approaches.
Purpose:
- To review key innovations in CHF management from 2014.
- To align therapeutic strategies with European Society of Cardiology guidelines.
Summary:
- Discusses enhancements in existing treatments, including beta-blockers and mineralocorticoid receptor antagonists.
- Explores novel pharmacological agents, notably angiotensin receptor neprilysin inhibitors.
- Presents updated insights into managing common comorbidities like atrial fibrillation and hyperkalemia.
Impact:
- Provides clinicians with current evidence-based strategies for optimizing CHF care.
- Facilitates the integration of new therapeutic options into clinical practice.
- Improves patient outcomes by addressing complex comorbidities in heart failure management.
Abstract:
Chronic heart failure is one of the most common chronic diseases worldwide with increasing prevalence and incidence. Due to the high morbidity and mortality a standardized and evidence-based therapy is crucial. The present review article gives an overview about the innovations in 2014 based on the current guidelines of the European Society of Cardiology. First, improvements in established medication regimens regarding beta blockers and mineralocorticoid receptor antagonists as well as treatment options for heart rate reduction will be explained. Second, new pharmacological developments, such as angiotensin receptor neprilysin inhibition will be discussed. Finally, new insights into common comorbidities of patients with chronic heart failure, such as atrial fibrillation and hyperkalemia will be presented.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Heart Failure II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy V: Interprofessional Care

